Supplementary Table 1 from Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling

Schoumacher, Marie; Hurov, Kristen E.; Lehár, Joseph; Yan-Neale, Yan; Mishina, Yuji; Sonkin, Dmitriy; Korn, Joshua M.; Flemming, Daisy; Jones, Michael D.; Antonakos, Brandon; Cooke, Vesselina G.; Steiger, Janine; Ledell, Jebediah; Stump, Mark D.; Sellers, William R.; Danial, Nika N.; Shao, Wenlin

doi:10.1158/0008-5472.22403511.v1

Supplementary Table 1 from Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling

https://doi.org/10.1158/0008-5472.22403511

journal contribution

posted on 2023-03-30, 22:45 authored by Marie Schoumacher, Kristen E. Hurov, Joseph Lehár, Yan Yan-Neale, Yuji Mishina, Dmitriy Sonkin, Joshua M. Korn, Daisy Flemming, Michael D. Jones, Brandon Antonakos, Vesselina G. Cooke, Janine Steiger, Jebediah Ledell, Mark D. Stump, William R. Sellers, Nika N. Danial, Wenlin Shao

<p>PDF file - 81KB, List of identified synergistic cell lines for TNKSi/MEKi combination in the large-scale combination screen and their KRAS status. KRAS mutants are in red.</p>

History

Related Materials

1.
DOI - Is supplement to Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling

ARTICLE ABSTRACT

Tankyrases (TNKS) play roles in Wnt signaling, telomere homeostasis, and mitosis, offering attractive targets for anticancer treatment. Using unbiased combination screening in a large panel of cancer cell lines, we have identified a strong synergy between TNKS and MEK inhibitors (MEKi) in KRAS-mutant cancer cells. Our study uncovers a novel function of TNKS in the relief of a feedback loop induced by MEK inhibition on FGFR2 signaling pathway. Moreover, dual inhibition of TNKS and MEK leads to more robust apoptosis and antitumor activity both in vitro and in vivo than effects observed by previously reported MEKi combinations. Altogether, our results show how a novel combination of TNKS and MEK inhibitors can be highly effective in targeting KRAS-mutant cancers by suppressing a newly discovered resistance mechanism. Cancer Res; 74(12); 3294–305. ©2014 AACR.

Usage metrics

Keywords

Drug Mechanisms Cellular responses to anticancer drugs Gastrointestinal Cancers Colorectal cancer

Licence

CC BY

Supplementary Table 1 from Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR2 Feedback Signaling

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports